… the cost, timing and results of preclinical studies and clinical trials and other development activities by us and … by the ongoing COVID-19 pandemic; the likelihood of our clinical programs being executed on timelines provided and … trials, including as a result of differences in the trial designs and protocols across different trials; the …
… Epidermolysis Bullosa The funding will be used for the clinical development of QR-313 Clinicaltrial in DEB patients to start in the second quarter of 2018 …
… Results Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated … host an “Analyst Event” on November 18, 2021 to highlight clinical stage pipeline programs and Axiomer ® RNA editing … Specialists (EURETINA) virtual congress. Earlier-stage clinical pipeline: The Company anticipates sharing initial …
… ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10 Study did not … product candidates, including sepofarsen (QR-110) and the clinical development and the therapeutic potential thereof, … the cost, timing and results of preclinical studies and clinical trials and other development activities by us and …
Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10
Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020
QR-1123 Investigational New Drug application active for autosomal dominant re
… in 2019 thus far with the initiation of both the Phase 2/3 trial for sepofarsen and the proof of concept trial for … 2019, the first patient was dosed in the Phase 1/2 STELLAR clinicaltrial for QR-421a in patients with Usher syndrome …
… of 2018. “During the third quarter, we announced important clinical proof-of-concept data for QR-110, demonstrating a … (RD2018). In the interim analysis of the ongoing Phase 1/2 clinicaltrial, QR-110 demonstrated rapid and sustained improvement in …
… ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy … further potential. ProQR will present further non-clinical data for Axiomer ® and announce its internal … there are no pharmaceutical treatments approved or in clinical development that treat the vision loss associated …
… AX-0810 targeting NTCP and AX-1412 targeting B4GALT1 into clinical development in late 2024/early 2025. Financial … intends to advance AX-1412 targeting B4GALT1 to early clinical proof of concept stage, then would seek to partner … These risks and uncertainties include, among others, the clinical development activities to be performed by Théa and …